[{"id":"54b0572b-d8fb-48d8-acfb-e6927b1cd7aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03912064","created_at":"2021-01-18T19:15:12.856Z","updated_at":"2024-07-02T16:34:27.453Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT","source_id_and_acronym":"NCT03912064","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2RA • ISG20","pipe":"","alterations":" ","tags":["IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • CD25hi Treg depleted DLI"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 05/24/2024","primary_completion_date":" 05/24/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-11"}]